Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2021 | Optimizing chemotherapy combinations for AML

Stéphane de Botton • 14 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Ivosidenib

Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, comments on the optimization of chemotherapy combinations for the treatment of acute myeloid leukemia (AML), highlighting the importance of considering the safety profile. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Stéphane de Botton

Updates on established therapies in AML 19:03
Updates on established therapies in AML
Jessica Altman et al. • 20 Sep 2025
A Phase II study evaluating the safety and efficacy of olutasidenib in patients with R/R mIDH1 AML 3:52
A Phase II study evaluating the safety and efficacy of olutasidenib in patients with R/R mIDH1 AML
Stéphane de Botton • 28 Nov 2022
The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML 6:53
The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML
Stéphane de Botton • 28 Nov 2022
Treatment strategies for patients with AML who possess a FLT3 mutation 2:15
Treatment strategies for patients with AML who possess a FLT3 mutation
Stéphane de Botton • 28 Nov 2022

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals